Aspireo Pharmaceuticals Overview
- Founded
-
2010
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$33.2M
Aspireo Pharmaceuticals General Information
Description
Developer of somatostatin analogs for the treatment of diseases resulting from hormone-active tumors. The company offers Somatoprim, a novel somatostatin analog used to treat patients with disorders such as diabetic retinopathy and cushings diseases.
Contact Information
Primary Office
- PO Box 880
- Ra'anana 43108
- Israel
Aspireo Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 30-Jun-2015 | $33.2M | 000.00 | Completed | Generating Revenue | |
| 1. Early Stage VC | 01-Dec-2010 | Completed | Startup |
Aspireo Pharmaceuticals Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Carsten Dehning | Chief Executive Officer & Chairman | ||
| Ian Hunneyball Ph.D | Chief Scientific Officer & Consultant | ||
| Shaun Marcus | Chief Financial Officer & Director |
Aspireo Pharmaceuticals Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Carsten Dehning | Aspireo Pharmaceuticals | Chief Executive Officer & Chairman | 000 0000 |
Aspireo Pharmaceuticals Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| TVM Capital Life Science | Venture Capital | Minority | 000 0000 | 000000 0 |